The Effect of NovoMix 30, Levemir or NovoRapid (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-Diabetic Medication. A 24-Week, International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Trial Profile

The Effect of NovoMix 30, Levemir or NovoRapid (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-Diabetic Medication. A 24-Week, International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary) ; Insulin aspart/insulin protamine aspart
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms A1chieve
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 20 Apr 2011 Actual end date reported as Dec 2010 by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top